H. S. Friedman, M. D. Prados, and P. Y. Wen, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, vol.27, pp.4733-4773, 2009.

T. N. Kreisl, L. Kim, and K. Moore, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, vol.27, pp.740-745, 2009.

T. Sandmann, R. Bourgon, and J. Garcia, Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial, J Clin Oncol, vol.33, pp.2735-2779, 2015.

J. Schwarzenberg, J. Czernin, and T. F. Cloughesy, Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy, Clin Cancer Res, vol.20, pp.3550-3559, 2014.

P. Kickingereder, M. Götz, and J. Muschelli, Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response, Clin Cancer Res, vol.22, pp.5765-71, 2016.

W. Taal, H. M. Oosterkamp, and A. M. Walenkamp, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, vol.15, pp.943-53, 2014.

A. A. Brandes, G. Finocchiaro, and V. Zagonel, AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma, Neuro Oncol, vol.18, pp.1304-1316, 2016.

O. L. Chinot, W. Wick, and W. Mason, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma, N Engl J Med, vol.370, pp.709-731, 2014.

M. R. Gilbert, J. J. Dignam, and T. S. Armstrong, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, vol.370, pp.699-708, 2014.

U. Herrlinger, N. Schäfer, and J. P. Steinbach, Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial, J Clin Oncol, vol.34, pp.1611-1620, 2016.

W. Wick, R. Stupp, and T. Gorlia, Phase II part of EORTC study 26101: the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma, J Clin Oncol, vol.34, 2016.

R. Stupp, W. P. Mason, and M. J. Van-den-bent, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005.

S. J. Pocock and R. Simon, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, vol.31, pp.103-118, 1975.

L. S. Freedman and S. J. White, On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial, Biometrics, vol.32, pp.691-695, 1976.

P. Y. Wen, D. R. Macdonald, and D. A. Reardon, Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria, J Clin Oncol, vol.28, pp.222-231, 2010.

B. Wiestler, D. Capper, and V. Hovestadt, Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial, Neuro Oncol, vol.16, pp.1630-1638, 2014.

P. Bady, D. Sciuscio, and A. C. Diserens, MGMT methylation analysis of glioblastoma on the Infinium methylation Bead-Chip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathol, vol.124, pp.547-60, 2012.

M. J. Taphoorn, L. Claassens, and N. K. Aaronson, An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing healthrelated quality of life and symptoms in brain cancer patients, Eur J Cancer, vol.46, pp.1033-1073, 2010.

P. M. Fayers, P. Hopwood, A. Harvey, D. J. Girling, D. Machin et al., Quality of life assessment in clinical trialsguidelines and a checklist for protocol writers: the U.K. Medical Research Council experience, Eur J Cancer, vol.33, pp.20-28, 1997.

F. Efficace, A. Bottomley, and D. Osoba, Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials -does HRQOL evaluation in prostate cancer research inform clinical decision making?, J Clin Oncol, vol.21, pp.3502-3513, 2003.

A. M. Shapiro, R. H. Benedict, D. Schretlen, and J. Brandt, Construct and concurrent validity of the Hopkins Verbal Learning Test-Revised, Clin Neuropsychol, vol.13, issue.23, pp.348-58, 1995.

A. L. Benton, K. Hamsher, B. M. Ellingson, M. Bendszus, and J. Boxerman, Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials, Iowa City: AJA Associates, vol.25, pp.1188-98, 1989.

L. Dirven, M. J. Van-den-bent, and A. Bottomley, The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial, 27. Wick W, Weller M, van den Bent M, et al. MGMT testing -the challenges for biomarker-based glioma treatment, vol.51, pp.372-85, 2014.